Business
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering
About this update from Shattuck Labs, Inc.
[{"type":"text","content":"AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2023. “Throughout 2022, we focused on clinical execution to position ourselves for key clinical data readouts for SL-172154 in 2023. These milestones are now rapidly approaching for both solid tumor and hematologic indications. Importantly, in 2022 we completed the monotherapy dose-escalation study and selected a dose of SL-172154 to advance into combination studies with liposomal doxorubicin for patients with platinum-resistant ovarian cancer. In addition, we have established a collaboration with ImmunoGen to combine SL-172154 with mirvetuximab soravtansine, also in the platinum-resistant ovarian cancer patient population. As for our heme program, we are enrolling well and have advanced into the azacitidine combination cohorts for patients with AML or HR-MDS,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck Labs. “We are looking forward to sharing data in 2023 which we believe will establish SL-172154 as both a differentiated CD47 inhibitor and a CD40 agonist capable of fully activating the CD40 pathway in human cancer patients. We expect that these data will position Shattuck well for continued growth in the years ahead.” Key Accomplishments in 2022 ARC Platform SL-172154 (SIRPα-Fc-CD40L) Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancerDosed first patients in ongoing Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancerInitiated Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancerDosed first patients in first combination cohort with azacitidine in ongoing Phase 1A/B clinical trial of in SL-172154 in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS)Provided clinical data for intratumorally administered SL-172154 in Phase 1 clinical trial in squamous cell carcinoma of the head and ne...